vs

Side-by-side financial comparison of Dermata Therapeutics, Inc. (DRMA) and Lightwave Logic, Inc. (LWLG). Click either name above to swap in a different company.

Lightwave Logic, Inc. is the larger business by last-quarter revenue ($159.2K vs $92.8K, roughly 1.7× Dermata Therapeutics, Inc.). Dermata Therapeutics, Inc. runs the higher net margin — -1853.3% vs -3486.6%, a 1633.4% gap on every dollar of revenue. On growth, Lightwave Logic, Inc. posted the faster year-over-year revenue change (594.5% vs 531.8%).

Dermata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm developing novel targeted therapies for dermatological diseases including acne, psoriasis and inflammatory skin disorders. It serves U.S. patients and healthcare providers, advancing pipeline candidates through trials to address unmet dermatological care needs.

Lightwave Logic, Inc. is a technology firm specializing in the development of advanced electro-optic polymer materials and integrated photonic devices. Its solutions target data center, telecommunications, and optical networking segments, delivering higher data transmission speeds and lower energy consumption than traditional photonic technologies.

DRMA vs LWLG — Head-to-Head

Bigger by revenue
LWLG
LWLG
1.7× larger
LWLG
$159.2K
$92.8K
DRMA
Growing faster (revenue YoY)
LWLG
LWLG
+62.8% gap
LWLG
594.5%
531.8%
DRMA
Higher net margin
DRMA
DRMA
1633.4% more per $
DRMA
-1853.3%
-3486.6%
LWLG

Income Statement — Q3 FY2023 vs Q4 FY2025

Metric
DRMA
DRMA
LWLG
LWLG
Revenue
$92.8K
$159.2K
Net Profit
$-1.7M
$-5.5M
Gross Margin
99.2%
Operating Margin
-1953.3%
-3629.3%
Net Margin
-1853.3%
-3486.6%
Revenue YoY
531.8%
594.5%
Net Profit YoY
29.1%
-0.3%
EPS (diluted)
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DRMA
DRMA
LWLG
LWLG
Q4 25
$159.2K
Q3 25
$29.2K
Q2 25
$25.6K
Q1 25
$22.9K
Q4 24
$22.9K
Q3 24
$22.9K
Q1 24
$30.4K
Q3 23
$92.8K
$0
Net Profit
DRMA
DRMA
LWLG
LWLG
Q4 25
$-5.5M
Q3 25
$-5.1M
Q2 25
$-5.0M
Q1 25
$-4.7M
Q4 24
$-5.5M
Q3 24
$-5.3M
Q1 24
$-5.7M
Q3 23
$-1.7M
$-5.2M
Gross Margin
DRMA
DRMA
LWLG
LWLG
Q4 25
99.2%
Q3 25
Q2 25
86.5%
Q1 25
91.2%
Q4 24
95.7%
Q3 24
94.6%
Q1 24
83.0%
Q3 23
Operating Margin
DRMA
DRMA
LWLG
LWLG
Q4 25
-3629.3%
Q3 25
-17757.5%
Q2 25
-19137.6%
Q1 25
-21405.0%
Q4 24
-24879.3%
Q3 24
-23115.3%
Q1 24
-19235.5%
Q3 23
-1953.3%
Net Margin
DRMA
DRMA
LWLG
LWLG
Q4 25
-3486.6%
Q3 25
-17488.0%
Q2 25
-19397.1%
Q1 25
-20495.8%
Q4 24
-24150.3%
Q3 24
-23131.9%
Q1 24
-18673.5%
Q3 23
-1853.3%
EPS (diluted)
DRMA
DRMA
LWLG
LWLG
Q4 25
$-0.04
Q3 25
$-0.04
Q2 25
$-0.04
Q1 25
$-0.04
Q4 24
$-0.05
Q3 24
$-0.04
Q1 24
$-0.05
Q3 23
$-0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DRMA
DRMA
LWLG
LWLG
Cash + ST InvestmentsLiquidity on hand
$6.6M
$69.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$6.4M
$74.6M
Total Assets
$7.3M
$79.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DRMA
DRMA
LWLG
LWLG
Q4 25
$69.0M
Q3 25
$34.9M
Q2 25
$22.1M
Q1 25
$25.0M
Q4 24
$27.7M
Q3 24
$26.9M
Q1 24
$31.5M
Q3 23
$6.6M
$30.9M
Stockholders' Equity
DRMA
DRMA
LWLG
LWLG
Q4 25
$74.6M
Q3 25
$41.2M
Q2 25
$28.8M
Q1 25
$31.5M
Q4 24
$33.4M
Q3 24
$33.5M
Q1 24
$37.2M
Q3 23
$6.4M
$35.4M
Total Assets
DRMA
DRMA
LWLG
LWLG
Q4 25
$79.2M
Q3 25
$44.8M
Q2 25
$32.4M
Q1 25
$35.6M
Q4 24
$37.8M
Q3 24
$37.2M
Q1 24
$41.7M
Q3 23
$7.3M
$39.1M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DRMA
DRMA
LWLG
LWLG
Operating Cash FlowLast quarter
$-3.3M
Free Cash FlowOCF − Capex
$-3.7M
FCF MarginFCF / Revenue
-2319.2%
Capex IntensityCapex / Revenue
237.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-15.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DRMA
DRMA
LWLG
LWLG
Q4 25
$-3.3M
Q3 25
$-3.2M
Q2 25
$-3.8M
Q1 25
$-3.5M
Q4 24
$-3.1M
Q3 24
$-3.6M
Q1 24
$-4.8M
Q3 23
$-2.9M
Free Cash Flow
DRMA
DRMA
LWLG
LWLG
Q4 25
$-3.7M
Q3 25
$-3.2M
Q2 25
$-3.8M
Q1 25
$-4.3M
Q4 24
$-3.5M
Q3 24
$-3.9M
Q1 24
$-5.5M
Q3 23
$-3.7M
FCF Margin
DRMA
DRMA
LWLG
LWLG
Q4 25
-2319.2%
Q3 25
-11093.4%
Q2 25
-14881.6%
Q1 25
-18953.9%
Q4 24
-15134.1%
Q3 24
-17193.6%
Q1 24
-18238.4%
Q3 23
Capex Intensity
DRMA
DRMA
LWLG
LWLG
Q4 25
237.9%
Q3 25
203.3%
Q2 25
157.6%
Q1 25
3724.5%
Q4 24
1448.6%
Q3 24
1525.8%
Q1 24
2549.2%
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons